Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
wouldn't want to be short here either. my guess is that the break of the SMA50 is inevitable and when its done the price will be rocketing, fueled by shorts and traders waiting on that break.
LIQD $1.95 read it yesterday:
@teacuppiglets: Another great potential short is $LIQD the 50 day MA is a wall this stock has not been able to get through.
Another great potential short is $LIQD the 50 day MA is a wall this stock has not been able to get through.
— Mr. Garlick (@realstocksnews) July 8, 2014
read it yesterday:
@teacuppiglets: Another great potential short is $LIQD the 50 day MA is a wall this stock has not been able to get through.
Another great potential short is $LIQD the 50 day MA is a wall this stock has not been able to get through.
— Mr. Garlick (@realstocksnews) July 8, 2014
i'm sure they only forgot to mention NEWL. lol.
LIQD & ERB both on the final Russell microcap index additions list as of 06/27/14. maybe that has something to do with the recent volume too. some PRs would be nice.
http://www.russell.com/indexes/americas/tools-resources/reconstitution/additions-deletions.page#indexes
that would be nice. i have some shares here at a low average. being waiting for that baby to take off. GL
$ERB definitly need to break the SMA50, but the chart looks very promising of doing so the next few days
350k shares @$2.00 bought in a block trade today. that's a lot of money for a dead stock.
LIQD new institutional position friday AH.
looks like Michael Dell believes in LIQD.
Initial Statement of Beneficial Ownership.
MSDC Management (GP), LLC
(a) Amount beneficially owned: 6,000,000
(b) Percent of class: 10.6%
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001123292-14-000577%2Etxt&FilePath=%5C2014%5C05%5C30%5C&CoName=LIQUID+HOLDINGS+GROUP%2C+INC%2E&FormType=SC+13G&RcvdDate=5%2F30%2F2014&pdf=
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001123292-14-000578%2Etxt&FilePath=%5C2014%5C05%5C30%5C&CoName=LIQUID+HOLDINGS+GROUP%2C+INC%2E&FormType=3&RcvdDate=5%2F30%2F2014&pdf=
http://www.nasdaq.com/quotes/institutional-portfolio/msdc-management-lp-850077
Sequans powered LTE tablets on stage at Indy 500 in LTE Multicast demos of Verizon Wireless http://t.co/otuWmiuH9f pic.twitter.com/4PPgSKloJa
— SEQUANS (@Sequans) May 24, 2014
SQNS tweet. http://www.verizonwireless.com/news/article/2014/05/verizon-wireless-lte-multicast.html
Verizon Wireless continues to innovate with a wide range of partners to deliver LTE Multicast. This month’s first demonstration on the commercial 4G LTE network uses network equipment from Ericsson. Devices used are enhanced Samsung Galaxy Note® 3 smartphones, featuring Multicast-capable chipsets, broadcast middleware, and multimedia services from Qualcomm Technologies, as well as Sequans demo tablets with Expway middleware. MobiTV supported the effort with application development, content management and delivery across multiple devices.
do they have their own tablets...? any ideas?
good to see a french company getting its footprint in france at a tennis grand slam the whole world is watching.
nice find
$IMUC - huge bids @$1.28/1.29 worth 390k shares now.
edit: now 500k shares @$1.30
ERB - i tried all day to get 3k shares @$1.49 but only got a partial fill for 123 shares though the SP went to $1.48. then i got 100 shares @$1.51 and later i got my fill after raising my bid to $1.55 eod.
there are some games played by MMs with ERB but no one trying to get out, imo.
here's the official date - so where's the PR?
The committee will discuss the potential cardiovascular risk associated with products in the class of peripherally-acting opioid receptor antagonists and the necessity, timing, design and size of cardiovascular outcomes trials to support approval of products in the class for the proposed indication of opioid-induced constipation in patients taking opioids for chronic pain.
http://www.fda.gov/AdvisoryCommittees/Calendar/ucm397059.htm
SQNS - it's very telling that minutes after i bought 3k shares more @$1.66 it drops to $1.51. LOL
from the SLXP earnings cc:
Mario Vincent Corso - Mizuho Securities USA Inc., Research Division
I guess, as a corollary to the wholesaler inventory moves, were there any associated price increases across the Santarus line or on XIFAXAN? I guess, secondary to that, on the R&D side, was there anything unusual in the quarterly number there, on the $52 million? Or is that a decent run rate for now? And then, on RELISTOR, I'm just wondering how you're thinking about the FDA's response, 30 days post the panel. I mean, are you expecting a concrete yes or no? Or could it be a "Well, we need to discuss the recommendations from the panel and come to some kind of agreement"?
William P. Forbes - Chief Development Officer, Chief Medical Officer and Executive Vice President of Research & Development
Mario, this is Bill, and I'll take your last question first, I guess. And regarding the RELISTOR panel, I think as everybody understands, right now, that's going to -- it's scheduled for June 11 and 12. And we anticipate that the Federal Register will have an announcement on this early next week if, in fact, it gets confirmed at that point. So somewhere on Monday, Tuesday, you may see something in the Federal Register announcing that advisory committee. But as far as the response to our formal appeal on RELISTOR and the sNDA for non-cancer pain, I think that's hard to really know at this point in time whether or not that would come with a response that either has complete directions and finality to it or if they would actually be something that they might ask to go back to the GI Division for discussion. So I think that's a little bit of the unknown that we have right now of -- around this process. And I'm sorry if we're not answering your question more directly, but I think most people that have followed this story realize that we're in an unusual situation. So I think, for right now, the best I can tell you is I can't really know for sure exactly how that response will play out. I just know that the ODE3, which is the department that oversees GI amongst other therapeutic departments, will give us a response at that point in time.
fromt their earnings CC:
Basic and diluted loss per share was $0.14 in the first quarter 2014, based on 59.1 million shares outstanding, compared to a net of $0.17 in the fourth quarter, which was based on a 50.3 million shares. Basic and diluted loss per share was $0.24 in the first quarter of 2013.
so the O/S is 50.3M and the institutional holding is at 7.8M - for me that makes 15.5% of the O/S and a 42.5M free float if i read that numbers correct..?
NEPT - plant should already be reconstructed since 04/07/14
http://ih.advfn.com/p.php?pid=nmona&article=61610827
they signed a settlement with Enzymotec, their CEO has been set free by the major shareholders and they closed an offering back in march @$2.50. they're firing on all cylinder.
http://ih.advfn.com/p.php?pid=nmona&article=61984708
http://ih.advfn.com/p.php?pid=nmona&article=61983705
http://ih.advfn.com/p.php?pid=nmona&article=61329191
yeah, me too. i'm heavy disappointed because of their Q2 guidance. i mean having design wins is one pretty thing but not selling anything from this wins in two quarters smells funny. half a year should be enough time for every company to get its business going.
like you i'm waiting one more quarter and waiting for the next guidance. if it is as bad as this one then i'm out.
i surely would my friend, but being an austrian guy my knowledge of the US market is far not as good as yours.
why are you all sure it's a tab? maybe it's a notebook.
So far our mobile computing design wins, which includes tablet and notebook are all for the U.S. market, but we expect this to change next year. In addition to the Kurio 7-inch tablet for kids, which was announced at CES in January and the second non-identified design that we announced in the fourth quarter last year, we have now a new design win for a device to be sold by a major retailer in the U.S.
i know, but most of the offering went to institutional investors and they seemed to be pretty confident about SQNSs future. i was hoping for breakeven in 2014, but from the looks of the Q2 guidance it seems hardly achieveable.
nope. just disappointing. especially the outlook concerns me. they are cash sufficient for maybe 3Qs - so they may have to raise again or the sales are ramping up big in 2H14.
mine is ~$1.90 but i couldn't resist at this bargain price. sold some biotech crap instead *lol*
SQNS got me 2k shares @$2.31 today, though i already had my full position. couldn't resist. it has to bounce from the SMA200. to many good things to come here.
like so many other stocks. know what you own is key here.
i totally agree with you my friend and i haven't sold one share either. just wanted to draw a line between the really good china news, the gap up, thestreet news and the shares falling back down.
@SQNS i'm investing in the bigger picture but obviously not everybody is thinking and acting that way. i don't get the selling here though.
possible reason for the latest weakness despite really good news is a sell rating from thestreet
http://www.thestreet.com/story/12591136/1/why-sequans-communications-sqns-stock-is-up-today.html?puc=yahoo&cm_ven=YAHOO
killer volume !! over 2 million shares in less than 15 minutes. very nice. $1.47 so far
i thought that too and i still believe over the long haul it will be a favorable buy price. mine was $2.51.
hopefully the IBB recovery holds the course. below 230s was pretty ugly. GL
NEPT $2.24 nice news
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation") (Nasdaq:NEPT) (TSX:NTB), announced today that reconstruction of its Sherbrooke, Quebec, Canada production facility will be completed April 7, 2014. Neptune is currently conducting equipment and safety related tests at the plant and employees are being trained. Preoperational testing will start early April 2014, with actual production commencing upon receipt of all outstanding permits.
The Corporation continues to work with various government authorities, including those related to workers health & safety and the environment, to obtain all remaining permits to begin operations. Neptune has been actively working with these agencies during the construction process and has cooperated with them to implement their recommendations.
The new facility will have the capacity to produce more than 150 metric tons of krill oil annually. In addition, the plant has the required space to allow for a doubling of production capacity in the future, depending on demand
EOD from $0.765 to $0.83 on 689 shares. lmao. what a paint job but it makes the chart looking real good breaking the SMA200 on the daily and finishing green on highest volume since january 2013 on the weekly.
NEPT $2.52 slightly green - fighting the $IBB downward pressure.
link back for DD
NEPT $2.53 looks like (double) bottom found and @ last offering price of $2.50. TAs look like the bounce may start in the coming sessions.
some nice fundamentals too. BiotechMoney18 wrote a nice blog about it. ACST is a subsidiary of NEPT.
http://seekingalpha.com/instablog/10409981-biotechmoney18/2740823-10-reasons-why-neptune-technologies-and-bioresources-inc-nept-will-bring-significant-return-to-your-portfolio-in-coming-months
great buying opportunity, imo. i'm in @$2.51.
NEPT $2.53 slightly green - fighting the $IBB downward pressure